[HTML][HTML] Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast …
S Nakamoto, M Ikeda, S Kubo, M Yamamoto… - Scientific Reports, 2021 - nature.com
Although paclitaxel plus bevacizumab (PB) therapy is an effective chemotherapeutic regimen
for HER2-negative advanced breast cancer (ABC), predictive markers for its effectiveness …
for HER2-negative advanced breast cancer (ABC), predictive markers for its effectiveness …
Is the presence of edema and necrosis on T2WI pretreatment breast MRI the key to predict pCR of triple negative breast cancer?
…, T Hayashi, Y Tadokoro, J Watanabe, S Nakamoto… - European …, 2020 - Springer
Purpose Given that a pathological complete response (pCR) after neoadjuvant chemotherapy
(NAC) is an important prognostic factor, evaluating pretreatment imaging findings is …
(NAC) is an important prognostic factor, evaluating pretreatment imaging findings is …
Leptomeningeal metastasis in ER+ HER2-advanced breast cancer patients: a review of the cases in a single institute over a 15-year period
J Watanabe, K Mitsuya, S Nakamoto, H Harada… - Breast Cancer Research …, 2021 - Springer
Purpose While leptomeningeal metastasis (LM) from estrogen receptor-positive, HER2-negative
advanced breast cancer (ER + HER2-ABC) has a poor prognosis, the details of ER + …
advanced breast cancer (ER + HER2-ABC) has a poor prognosis, the details of ER + …
Dynamic changes in absolute lymphocyte counts during eribulin therapy are associated with survival benefit
S Nakamoto, M Ikeda, S Kubo, M Yamamoto… - Anticancer …, 2021 - ar.iiarjournals.org
Background/Aim: We investigated the usefulness of dynamic changes in absolute lymphocyte
count (ALC) and neutrophil-to-lymphocyte ratio (NLR) during eribulin therapy as predictive …
count (ALC) and neutrophil-to-lymphocyte ratio (NLR) during eribulin therapy as predictive …
The real-world outcomes of patients with advanced invasive lobular carcinoma of the breast compared with invasive ductal carcinoma: a review at a single institution
J Watanabe, S Nakamoto, T Sugino - Anticancer Research, 2021 - ar.iiarjournals.org
Background: The real-world outcomes of patients with advanced invasive lobular carcinoma
(ILC) of the breast are unclear because of its rarity. Patients and Methods: We identified 435 …
(ILC) of the breast are unclear because of its rarity. Patients and Methods: We identified 435 …
[HTML][HTML] Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study
S Nakamoto, J Watanabe, S Ohtani, S Morita… - Scientific Reports, 2021 - nature.com
Post-progression survival affects overall survival (OS) in patients with HER2-negative
advanced breast cancer (HER2-ABC); thus, the optimal choice of first-line chemotherapy (1LCT) …
advanced breast cancer (HER2-ABC); thus, the optimal choice of first-line chemotherapy (1LCT) …
[HTML][HTML] Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective …
S Nakamoto, J Watanabe, S Ohtani, S Morita, M Ikeda - BMC cancer, 2022 - Springer
Background Eribulin methylate (eribulin) improved the overall survival (OS) of eribulin-treated
patients with HER2-negative advanced breast cancer (ABC) in prospective and …
patients with HER2-negative advanced breast cancer (ABC) in prospective and …
Systemic immunity markers are associated with clinical outcomes of atezolizumab treatment in patients with triple-negative advanced breast cancer: a retrospective …
S Nakamoto, T Shien, M Itoh, Y Yamamoto… - Clinical and …, 2023 - Springer
Immune checkpoint inhibitors (ICI) are reportedly efficacious against triple-negative breast
cancer (TNBC) and are now recommended as first-line therapy. Systemic immunity markers, …
cancer (TNBC) and are now recommended as first-line therapy. Systemic immunity markers, …
Bevacizumab as first-line treatment for HER2-negative advanced breast cancer: paclitaxel plus bevacizumab versus other chemotherapy
S Nakamoto, J Watanabe, S Ohtani, S Morita, M Ikeda - in vivo, 2020 - iv.iiarjournals.org
… were performed by Shogo Nakamoto and Shoichiro Ohtani. Analysis was performed by
Shogo Nakamoto. The first draft of the article was written by Shogo Nakamoto and all Authors …
Shogo Nakamoto. The first draft of the article was written by Shogo Nakamoto and all Authors …
[HTML][HTML] The systemic immune markers at diagnosis can predict the survival benefit in advanced breast cancer
S Nakamoto, M Ikeda, S Kubo… - Cancer Diagnosis & …, 2021 - ncbi.nlm.nih.gov
… Shogo Nakamoto prepared the material preparation, collected the data, and performed
the analysis. Shogo Nakamoto also wrote the first draft of the manuscript, and all Authors …
the analysis. Shogo Nakamoto also wrote the first draft of the manuscript, and all Authors …